论文部分内容阅读
目的探讨双歧杆菌三联活菌胶囊对溃疡性结肠炎(UC)患者血清白介素(IL)-6、8和10水平的影响及疗效观察。方法选取88例UC患者,随机分为观察组和对照组。两组患者均酌情予以柳氮磺胺吡啶、5-氨基水杨酸和糖皮质激素等常规治疗。观察组患者在此基础上加用口服双歧杆菌三联活菌胶囊420mg/次,3次/d,连用8周。对照组患者除不使用双歧杆菌三联活菌胶囊外余治疗同观察组。观察两组患者治疗前后血清IL-6、8和10水平变化,并比较其临床疗效及不良反应。结果治疗8周后,两组患者血清IL-6、8水平明显下降,IL-10水平明显上升(P<0.05或P<0.01),且观察组下降值或上升值大于对照组(P<0.05);观察组患者总有效率明显高于对照组(χ2=4.42,P<0.05);治疗中对照组出现不良反应3例,观察组出现5例,症状均较轻,两组患者不良反应发生率比较差异无统计学意义(χ2=0.14,P>0.05)。结论双歧杆菌三联活菌胶囊治疗UC的疗效确切,安全性较好,作用与其能降低血清IL-6、8水平,提高血清IL-10水平,减轻肠黏膜局部炎症反应密切相关。
Objective To investigate the effects of Bifidobacterium triple viable capsule on the levels of serum interleukin (IL) -6, 8 and 10 in patients with ulcerative colitis (UC) and its therapeutic effect. Methods 88 patients with UC were randomly divided into observation group and control group. Patients in both groups were treated with sulfasalazine, 5-aminosalicylic acid and glucocorticoids as appropriate. On the basis of this observation, patients in the observation group were given oral Bifidobacterium triple viable capsule 420mg / time, 3 times / d for 8 weeks. Patients in the control group except for the use of bifidobacterium triple viable capsule outside the treatment with the observation group. The changes of serum IL-6, 8 and 10 levels in both groups before and after treatment were observed, and their clinical efficacy and adverse reactions were compared. Results After 8 weeks of treatment, the serum levels of IL-6 and 8 were significantly decreased and the level of IL-10 was significantly increased (P <0.05 or P <0.01) in both groups, and the values in the observation group were higher than those in the control group ). The total effective rate in the observation group was significantly higher than that in the control group (χ2 = 4.42, P <0.05). There were 3 adverse reactions in the control group and 5 in the observation group, with mild symptoms and adverse reactions in both groups The difference was not statistically significant (χ2 = 0.14, P> 0.05). Conclusions Bifidobacterium triple viable capsule is effective and safe for the treatment of UC, which is closely related to its effect on decreasing the serum level of IL-6 and 8, increasing the level of serum IL-10 and relieving the local inflammatory reaction of intestinal mucosa.